REALITI-A was an international, prospective, observational cohort study, investigating the real-world corticosteroid-sparing effect of mepolizumab in severe asthma. touchRESPIRATORY caught up with Dr. Cristiano Caruso (Columbus Hospital, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy) to discuss the aims, design, eligibility criteria and the 2 year findings from REALITI-A.
The abstract ‘International, prospective study of mepolizumab in severe asthma: REALITI-A at 2yr.‘ (Abstract number: PA4186) was presented at ERS 2022, 4–6 September, 2022.
Questions
- What are the challenges of treating severe asthma? (0:29)
- What clinical evidence supports the use of mepolizumab in severe asthma? (1:03)
- What were the aims, design and eligibility criteria of the REALITI-A study? (1:38)
- What were the findings at 2 years? (2:56)
- What were the conclusions of the investigators regarding the efficacy and safety findings? (4:27)
Disclosures: Cristiano Caruso discloses consulting for GSK.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
